SCHEMBL629052

SCHEMBL629052

CCCC(CC(=O)OC(C)(C)C)C(=S)OC

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.38
CA1 P00915 3/20 0.35
CA2 P00918 3/20 0.35
CA12 O43570 3/20 0.35
CA14 Q9ULX7 3/20 0.35
HDAC8 Q9BY41 2/20 0.35
HDAC6 Q9UBN7 2/20 0.35
HDAC7 Q8WUI4 1/20 0.35
HDAC9 Q9UKV0 1/20 0.35
HDAC5 Q9UQL6 1/20 0.35
CTSK P43235 5/20 0.35
CTSS P25774 2/20 0.35
BIRC2 Q13490 1/20 0.35
HDAC1 Q13547 2/20 0.34
HDAC2 Q92769 2/20 0.34
CHRM1 P11229 1/20 0.34
AKR1A1 P14550 1/20 0.34
CHRM3 P20309 1/20 0.34
HTR2A P28223 1/20 0.34
HTR2C P28335 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28240301 0.83 CA1 (0.49) CYP2D6CA1CA2CA12CA14
SCHEMBL25917050 0.83 CA1 (0.49) CYP2D6CA1CA2CA12CA14
SCHEMBL16310556 0.80 HDAC8 (0.39) CYP2D6CA1CA2CA12CA14
SCHEMBL7051239 0.80 HDAC1 (0.54) CYP2D6CA2HDAC8HDAC6HDAC7
SCHEMBL16798232 0.80 HDAC1 (0.54) CYP2D6CA2HDAC8HDAC6HDAC7
SCHEMBL6448846 0.80 HDAC1 (0.54) CYP2D6CA2HDAC8HDAC6HDAC7
SCHEMBL8258147 0.75 CA2 (0.61) CYP2D6CA1CA2CTSKCTSS
SCHEMBL24571120 0.73 CYP2D6 (0.41) CYP2D6CA1CA2CA12CA14
SCHEMBL11102245 0.72 CYP2D6 (0.44) CYP2D6CA1CA2CA12CA14
SCHEMBL1915651 0.71 CA2 (0.55) CYP2D6CA1CA2CTSKCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0986384-B1 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIV PITTSBURGH (US) 2012-02-22 EP disclosed
US-6310095-B1 INHIBITING OR TREATING CANCER, TREATING INTIMAL HYPERPLASIA ASSOCIATED WITH RESTENOSIS AND ATHEROSCLEROSIS, INHIBITING POST-TRANSLATIONAL MODIFICATION OF ONCOGENIC RAS PROTEIN BY PROTEIN FARNESYLTRANSFERASE AND/OR GERANYLGERANYLTRANSFERASE UNIVERSITY OF PITTSBURGH 2001-10-30 US disclosed